Cancer clinical trials in the region Auvergne-Rhône-Alpes

445 currently recruiting clinical trials

Looking for clinical trials?

Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:

Create your account
Copy-paste your latest medical report
Our AI-based assistant does the rest for you

Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:

Create your account

Phase 2 Lymphoma #NCT05283720 #2023-505347-38-00

Etude de l'innocuité et la tolérabilité de l'EPCORITAMAB en association avec des agents antinéoplasiques chez les participants adultes atteints d'un lymphome non hodgkinien - Bras 5

B cell lymphoma Follicular lymphoma 1 2 3 or more

Systemic Treatment-Naive Bispecific T-cell engager antibodies

8 recruiting sites

Abbvie

Phase 2 Lymphoma #NCT05283720 #2023-505347-38-00

Etude de l'innocuité et la tolérabilité de l'EPCORITAMAB en association avec des agents antinéoplasiques chez les participants adultes atteints d'un lymphome non hodgkinien - Bras 6

B cell lymphoma Mantel cell lymphoma None 1 2 3 or more

Bispecific T-cell engager antibodies

8 recruiting sites

Abbvie

Phase 2 Bladder / Urinary Tract / Urethral cancer #NCT03547973 #2023-508302-24-00

[TROPHY U-01] Étude du SACITUZUMAB GOVITECAN chez des participants atteints d'un cancer urothélial non résorbable ou propagé - Cohorte 7

Invasive bladder cancer Urothelial carcinoma Locally Advanced Metastatic None Systemic Treatment-Naive

19 recruiting sites

Gilead Sciences

Phase 2 Lung cancer #NCT03175224 #2024-514542-37-00

[SPARTA] APL-101 chez des patients atteints d'un CBNPC avec mutations c-MET entrainant le saut de l'EXON 14 - Cohorte C1

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic MET 1 2 3 or more Immunotherapy Chemotherapy

ALK BRAF EGFR KRAS G12C KRAS non G12C NTRK-1/2/3 RET ROS-1 Targeted therapy

5 recruiting sites

Apollomics

Phase 2 Lung cancer #NCT03175224 #2024-514542-37-00

[SPARTA] APL-101 chez des patients atteints d'un CBNPC avec mutations c-MET entrainant le saut de l'EXON 14 - Cohorte A2

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic MET 1 2 3 or more Immunotherapy Chemotherapy

ALK BRAF EGFR KRAS G12C KRAS non G12C NTRK-1/2/3 RET ROS-1 Targeted therapy

5 recruiting sites

Apollomics

Phase 2 Lung cancer #NCT03175224 #2024-514542-37-00

[SPARTA] APL-101 chez des patients atteints d'un CBNPC avec mutations c-MET entrainant le saut de l'EXON 14 - Cohorte A1

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic MET None Systemic Treatment-Naive

ALK BRAF EGFR KRAS G12C KRAS non G12C NTRK-1/2/3 RET ROS-1 Targeted therapy

5 recruiting sites

Apollomics

Phase 2 Lymphoma #NCT06534437 #2024-513098-31-00

[JASPIS-01] MEN1703 (SEL24) pour le traitement du lymphome non hodgkinien agressif à cellules B récidivant ou réfractaire

B cell lymphoma Large B cell lymphoma Indolent transformed lymphoma None 2 3 or more Chemotherapy Bispecific T-cell engager antibodies Monoclonal antibodies

Systemic Treatment-Naive

7 recruiting sites

Ryvu Therapeutics SA

Phase 2 Lung cancer #NCT06552234

Étude d'efficacité de phase II du REPOTRECTINIB chez les patients fragiles et/ou âgés atteints d'un cancer bronchique non à petites cellules avancé avec réarrangement du gène ROS1

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic ROS-1 None 1 2 3 or more Systemic Treatment-Naive Immunotherapy Chemotherapy Targeted therapy

20 recruiting sites

Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer

Phase 2 Lung cancer #NCT05384626 #2024-514266-39-00

[ALKOVE-1] Etude du NVL-655 chez des patients atteints de CPNPC avancé et d'autres tumeurs solides hébergeant un réarrangement ALK ou activant une mutation ALK - cohortes 2a à 2e

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic ALK 1 2 3 or more Immunotherapy Chemotherapy Targeted therapy

Systemic Treatment-Naive

4 recruiting sites

Nuvalent Inc.

Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer #NCT05384626 #2024-514266-39-00

[ALKOVE-1] Etude du NVL-655 chez des patients atteints de CPNPC avancé et d'autres tumeurs solides hébergeant un réarrangement ALK ou activant une mutation ALK - cohorte 2f

Locally Advanced Metastatic Metastatic Castration-resistant ALK 1 2 3 or more

AKT ATM BRAF BRCA 1/2 CDK12 CHEK 1/2 ESR FGFR HER2 HOXB13 KRAS G12C KRAS non G12C MET MSI/dMMR NRAS NTRK-1/2/3 PALB2 PIK3CA PTEN RET Systemic Treatment-Naive

4 recruiting sites

Nuvalent Inc.